Abstract
Important advances have been achieved with molecular targeted agents in clinical oncology. Breast, colon, and lung cancer, are now commonly treated with a combination of chemotherapy and targeted agents. In this article the authors discuss the limitations of targeted therapy development, failures of previous studies, and possible strategies for an intelligent drug development. Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on K-RAS status are discussed.
Keywords: Targeted therapy, breast cancer, lung cancer, colorectal cancer, resistance, therapy individualization
Current Clinical Pharmacology
Title: Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives
Volume: 5 Issue: 3
Author(s): Otto Metzger-Filho, Camilo Moulin and Ahmad Awada
Affiliation:
Keywords: Targeted therapy, breast cancer, lung cancer, colorectal cancer, resistance, therapy individualization
Abstract: Important advances have been achieved with molecular targeted agents in clinical oncology. Breast, colon, and lung cancer, are now commonly treated with a combination of chemotherapy and targeted agents. In this article the authors discuss the limitations of targeted therapy development, failures of previous studies, and possible strategies for an intelligent drug development. Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on K-RAS status are discussed.
Export Options
About this article
Cite this article as:
Metzger-Filho Otto, Moulin Camilo and Awada Ahmad, Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives, Current Clinical Pharmacology 2010; 5 (3) . https://dx.doi.org/10.2174/157488410791498716
DOI https://dx.doi.org/10.2174/157488410791498716 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Regulation of Foxo-Dependent Transcription by Post-Translational Modifications
Current Drug Targets Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews The Possible Role of Infertility Drugs in Later Malignancy: A Review
Current Medicinal Chemistry Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders
Current Pharmaceutical Design Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic
Current Drug Targets Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer Development
Current Cancer Drug Targets The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab
Recent Patents on Biotechnology Synthesis, Characterization and Evaluation of 1,3-Bisindolyl-2-Propen-1- One Derivatives as Potent Anti-Breast Cancer Agents
Current Bioactive Compounds Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment
Mini-Reviews in Medicinal Chemistry Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension
Current Pharmaceutical Design Semi-Automatic Synthesis of Distamycin Analogues and their DNA Binding Properties
Letters in Drug Design & Discovery Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers
Current Cancer Drug Targets Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening SCAP/SREBPs are Central Players in Lipid Metabolism and Novel Metabolic Targets in Cancer Therapy
Current Topics in Medicinal Chemistry Enhancing Endothelial Progenitor Cell Function Through Selective Estrogen Receptor Modulation: A Potential Approach to Cardiovascular Risk Reduction
Cardiovascular & Hematological Agents in Medicinal Chemistry Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology: An Update
Current Medicinal Chemistry Hypoglycemic Agents in the Management of Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology